USD 11.25
(5.79%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 12.05 Billion USD | 10.07% |
2022 | 10.95 Billion USD | 2.57% |
2021 | 10.68 Billion USD | 2.37% |
2020 | 10.43 Billion USD | -1.08% |
2019 | 10.54 Billion USD | 0.51% |
2018 | 10.49 Billion USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 11.89 Billion USD | -1.38% |
2024 Q3 | 12.75 Million USD | 4.92% |
2024 Q2 | 12.15 Billion USD | 2.21% |
2023 Q1 | 10.76 Billion USD | -1.75% |
2023 FY | 12.05 Billion USD | 10.07% |
2023 Q4 | 12.05 Billion USD | 9.5% |
2023 Q3 | 11.01 Billion USD | 0.3% |
2023 Q2 | 10.97 Billion USD | 2.01% |
2022 Q3 | 10.43 Billion USD | -1.67% |
2022 Q2 | 10.61 Billion USD | 0.16% |
2022 Q1 | 10.59 Billion USD | -0.79% |
2022 FY | 10.95 Billion USD | 2.57% |
2022 Q4 | 10.95 Billion USD | 4.96% |
2021 Q3 | 11.33 Billion USD | 3.91% |
2021 Q2 | 10.9 Billion USD | 13.13% |
2021 FY | 10.68 Billion USD | 2.37% |
2021 Q1 | 9.64 Billion USD | -7.59% |
2021 Q4 | 10.68 Billion USD | -5.77% |
2020 Q4 | 10.43 Billion USD | 0.0% |
2020 FY | 10.43 Billion USD | -1.08% |
2020 Q1 | - USD | 0.0% |
2019 FY | 10.54 Billion USD | 0.51% |
2018 FY | 10.49 Billion USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
AbbVie Inc. | 134.71 Billion USD | 91.049% |
Bristol-Myers Squibb Company | 95.15 Billion USD | 87.329% |
Bristol-Myers Squibb Company Ce | 95.15 Billion USD | 87.329% |
Johnson & Johnson | 167.55 Billion USD | 92.804% |
Eli Lilly and Company | 64 Billion USD | 81.161% |
Merck & Co., Inc. | 106.67 Billion USD | 88.697% |
Novartis AG | 99.94 Billion USD | 87.935% |
Pfizer Inc. | 226.5 Billion USD | 94.676% |